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Abstract 
Tissue-engineering strategies to stimulate bone regeneration may offer an alternative approach to conventional orthopaedic and 
maxillofacial surgical therapies. Over the last decade, significant advances have been accomplished in developing biomimetic ma- 
trices, growth factors, cell transplantation and gene delivery therapeutics to support new bone growth. However, it is not known if 
tissue-engineered bone recapitulates the biology of normal skeletal tissue in response to  physiologic cues. Here, we report that bone 
formed by the differentiation of transplanted murine bone marrow stromal cells (BMSCs) responds to  a systemically delivered 
calciotropic hormone. Ectopic ossicles in mice exposed to catabolic doses of parathyroid hormone (PTH) had increased numbers of 
tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts as compared to control mice. In contrast, treatment with anabolic 
doses of PTH promoted a marked increase in trabecular bone mass as analyzed by microcomputed tomography and histo- 
morphometry. Our findings demonstrate that bone formed from transplanted BMSCs is responsive to normal physiologic signals, 
and can be augmented by the addition of a systemic anabolic agent. Because multiple and distinct ossicles can be generated in a 
single animal, this versatile system may be used to: (a) elucidate cellularlmolecular mechanisms in bone regeneration; (b) study cell- 
to-cell interactions in the bone marrow microenvironment in health and disease; and (c) evaluate the efficacy of osteotropic agents 
that modulate bone turnover in vivo. 
0 2003 Orthopaedic Research Society. Published by Elsevier Ltd. All rights reserved. 
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Introduction 
Remarkable advances have been made to stimulate 
new bone growth via tissue-engineering strategies [26,30]. 
Biomimetic matrices, growth factors, cell transplanta- 
tion and gene delivery therapeutics have all been utilized 
to optimize and support bone regeneration [S, 16,251. 
Despite recent developments, little attention has been 
given to determine if engineered bone responds to nor- 
mal physiologic cues. Because the ultimate goal of bone 
tissue engineering is to recapitulate the structure and 
function of the native tissue it is designed to replace, it is 
critical to evaluate in well-characterized model systems 
*Corresponding author. Tel.: +1-734-936-2600; fax: +1-734-764- 
2469. 
E-mail address: paulk@umich.edu (P.H. Krebsbach). 
whether this newly formed bone mimics normal skeletal 
tissue. Bone marrow stromal cells (BMSCs), also re- 
ferred to as mesenchymal or skeletal stem cells, give rise 
to a variety of tissues of mesenchymal origin including 
bone [2,24]. Indeed, BMSC transplantation strategies 
have been applied to generate ectopic as well as ortho- 
topic bone, the latter being a potential approach for 
skeletal regeneration procedures [4,13,17,23]. However, 
it is not known if tissue-engineered bone generated by 
osteogenic cell transplantation responds to systemic bio- 
logic factors in a similar manner as native bone. 
The purpose of this study was to characterize the 
remodeling of tissue-engineered bone developed from 
the differentiation of transplanted murine BMSCs in 
response to catabolic and anabolic regimens of sys- 
temically administered recombinant human parathy- 
roid hormone (PTH). As a major calciotropic peptide 
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hormone, PTH plays a critical role in regulating extra- 
cellular calcium homeostasis. In addition, PTH is ca- 
pable of stimulating both catabolic and anabolic actions 
in bone, depending on the dose and mode of adminis- 
tration [l  I]. Our findings demonstrate that tissue- 
engineered bone exposed to catabolic doses of PTH had 
increased osteoclastic activity, whereas treatment with 
anabolic doses resulted in increased trabecular bone 
mass. These studies suggest that bone developed from 
transplanted BMSCs responds to normal physiologic 
signals, and can be augmented by the addition of a 
systemic anabolic agent. 
Materials and methods 
Isolation O~BMSC.F. our- to 8-week old C57BL/6 littermate mice 
were used to isolate BMSCs from the femoral, tibia1 and humeral 
cavities (six bones per animal) as previously described [ I  51. Fibroblast- 
like BMSCs are the predominant adherent cell type when bone marrow 
is cultured in vitro and they lack the basic characteristics of macro- 
phages and endothelial cells [5,9]. First passage was carried out on day 
10 when a confluent adherent cell layer was observed. Cultures were 
maintained for 5-7 days before cells were transplanted. All animal 
protocols were performed in compliance with the University of 
Michigan Committee for the Use and Care of Animals. 
Surgicul trau.~~lau~utii~n of 6MSCs. Transplantation procedures 
were performed as previously described [IS]. Pooled BMSCs (passage 
2.2.5-3 x 10' cells) were resuspended in 30-100 pL of growth medium 
and incorporated into gelatin sponges (Gelfoam@'; Upjohn, Kalama- 
zoo, MI) by capillary action. Immunocompromised 4- to 6-week-old 
male mice (N:NIH-bg-nu-xid) were utilized as transplant recipients. 
Following anesthesia with an intraperitoneal injection of ketamine (90 
mg/kg) and xylazine (5 mg/kg), two midlongitudinal skin incisions of 
approximately 1 cm were made on the dorsal surface of each mouse. 
Subcutaneous pouches were formed by blunt dissection and four 
transplants were placed per animal. 
PTH treatments. One week following transplantation, two groups 
of animals (8-10 animalslgroup) were given daily subcutaneous injec- 
tions of either recombinant human PTH(1-34) (40 pg/kg) (Bachem, 
CA) or vehicle (0.9% sodium chloride) (Abbott, IL) for 21 days (ana- 
bolic regimen) [6]. Four weeks following transplantation, two groups 
of animals were injected subcutaneously with 50 pL of PTH(1-34) (2 
pg) or vehicle every 6 h for 3 days (catabolic regimen) [28]. At sacrifice, 
which was 24 h (anabolic group) or 2 h (catabolic group) after the last 
injection, terminal serum samples were collected (Fig. IA). 
Catabolic Or anilbOllC Subcutaneous 
PTH treatment transplant 
Rudiogruphy, microcomputed tomography (pCT),  histology and 
histomorphoi,ietry. Radiographic analysis was performed using a 
microradiography apparatus (Faxitron X-ray Corporation, IL). For 
pCT analysis, specimens were scanned at 8.93 pm voxel resolution 
on an EVS Corp. pCT scanner. Morphometric measures were cal- 
culated using custom programs in IDL version 5.5. For histology, 
the ossicles were fixed in aqueous buffered zinc formalin for 24 h at 
4 "C, decalcified 2 days in 10% EDTA, embedded in paraffin and 5- 
pm serial sections prepared and stained with hematoxylin/eosin. 
Sections from the catabolic group were also used for tartrate- 
resistant acid phosphatase (TRAP) staining using a leukocyte acid 
phosphatase kit from Sigma Diagnostics (St Louis, MO). Total bone 
area, trabecular bone area, cortical width, number of osteocytes/mm2 
and number of TRAP+ osteoclasts/mm were analyzed by computer- 
assisted histomorphometry using Image Pro Plus 4.1 (Media Cy- 
bernetics, Silver Spring, MD) and SPOT RT Diagnostic Inst. 3.0 
(Sterling Heights, MI) software interfaced with a Nikon Eclipse 
E800 hght/epifluorescent microscope (Nikon, Melville, NY) as pre- 
viously described [19]. Histomorphometric determination of the cor- 
tical width was analyzed by carefully delineating the endocortical 
area without including any trabecular structure emerging from the 
endosteum. 
Serum biochemistry. Serum calcium concentrations were deter- 
mined by a colorimetric assay with cresophtalein complexone follow- 
ing the manufacturer's recommendations (Sigma Diagnostics). 
Stutistics. The data was analyzed using Student's t test with the 
Instat 2.1 biostatistics program (GraphPad Software, San Diego, CA). 
Data are presented as mean + SEM. 
Results 
We characterized the responses of BMSC-derived 
bone to systemic PTH administered in a catabolic and 
anabolic regimen. Following transplantation into a host 
animal, BMSCs seeded in gelatin sponges, formed self- 
contained, highly vascularized, mineralized bone/bone 
marrow organs (Fig. 1B and C). These ectopic ossicles 
contained cortical and trabecular bone surrounding a 
normal marrow cavity with active hematopoiesis as 
previously described [ 151. Because hematopoietic mar- 
row functions as the major source of osteoclast pre- 
cursors [29], we first investigated whether a catabolic 
regimen of PTH could induce the recruitment and ac- 
tivity of functional osteoclasts to the endosteal and 
Fig. 1. Experimental design to characterize remodeling responses of tissue-engineered bone generated from transplanted murine bone marrow 
stromal cells (BMSCs). (A) Schematic of experimental procedures. Subcutaneous injections with either anabolic or catabolic doses of PTH( 1-34) were 
initiated 1 or 4 weeks after cell transplantation, respectively, followed by sacrifice and endpoint assays. (B) Gross photograph of ossicles at sacrifice, 
and (C) radiograph of mineralized nodules (arrows) prior to their excision. 
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trabecular surfaces of the ossicles. Four weeks after cell 
transplantation, mice were administered either PTH (2 
pg) or saline as a vehicle control, subcutaneously four 
times a day for 3 days, then sacrificed. Animals treated 
with PTH had significantly higher serum calcium con- 
centrations than controls (12.12 k 0.6 mg/dL (PTH) 
versus 9.93 k0 .3  mg/dL (vehicle), p < 0.02, Fig. 2A). 
Under normal circumstances serum calcium levels are 
very similar in mice as compared to humans, ranging 
between 8.5 and 10.5 mg/dL. Interestingly, these simi- 
larities are also true in hypercalcemic states associated 
with diseases such as primary hyperparathyroidsm. In 
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model of human primary hyperparathyroidsm serum 
calcium levels were significantly elevated as compared 
to their wild-type littermates [12]. Serum calcium levels 
in the transgenic mice were between 1 1.4 and 12.45 mg/ 
dL. In most patients with primary hyperparathyroidsm 
serum calcium levels are within 1 mg/dL above the 
upper limits of normal and usually <I2 mgldL [27]. 
Therefore, our results in PTH-treated mice are com- 
parable to what it is clinically observed in patients with 
primary hyperparathyroidsm. The endosteal and trab- 
ecular surfaces of the ossicles also contained a consid- 
erably higher number of TRAP-positive osteoclast-like 
cells per millimeter of bone (3.93 i 0.7 (PTH) versus 
5 ,  + 
Vehicle PTH 
Fig. 2. PTH induced a catabolic response in ectopic tissue-engineered bone. (A) Calcemic responses in mice treated with catabolic doses of PTH 
( n  = 9) or vehicle control ( n  = 6), * p  < 0.02. (B) Quantification of TRAP-positive osteoclast-like cells in ossicles exposed to catabolic doses of PTH 
( n  = 9) versus controls ( n  = 8), ’ p  < 0.01. Osteoclast-like cells were found lining endosteal (C) and trdbecuh’ bone surfaces (D) (arrowheads) with 
higher cellularity adjacent to endosteal surfaces of PTH-treated ossicles (E) as  compared to controls which demonstrated minimal TRAP positive 
stain (F) and less cellularity (G).  
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1.65 2C0.3 (vehicle), p < 0.01, Fig. 2 B-D) and dem- 
onstrated an increased overall cellularity in close 
proximity to scalloped endosteal surfaces (Fig. 2E). In 
contrast, ossicles in vehicle-treated animals showed 
minimal TRAP-positive activity and cellularity (Fig. 2F 
and G). Interestingly, similar osteoclastic responses 
have been reported when localized catabolic doses of 
PTH are directly delivered to rat femurs [28]. Taken 
together, these data suggest that the hematopoietic 
marrow contained in the ectopic ossicles was able to 
support osteoclastic activity following systemic delivery 
of a potent stimulator of bone resorption such as PTH. 
Next, the ability of the tissue-engineered bone to re- 
spond to an anabolic course of PTH was evaluated using 
an intermittent PTH dosing regimen. Daily subcutane- 
ous injections of either PTH (40 pg/kg) or saline were 
initiated 1 week following BMSC transplantation and 
continued for 21 days, before the mice were sacrificed. 
Following surgical excision, microradiographic images 
of ossicles from PTH- and vehicle-treated mice were 
taken to determine their degree of mineralization. Rep- 
resentative ossicles derived from PTH-treated mice re- 
vealed a higher degree of radiopacity consistent with 
an increase in mineral content as compared to controls 
(Fig. 3A). These observations were further supported 
and quantified by histomorphometric analysis. Relative 
to the total area of the ossicle, the trabecular bone area 
was significantly higher in ossicles derived from PTH- 
treated mice (37.04 2C 7.4% (PTH) versus 14.05 2C 2.13% 
(vehicle), p < 0.05, Fig. 3B and C). These positive 
changes in bone microarchitecture correlated with higher 
cellularity in the marrow cavity, a qualitative reduction 
in marrow fat content and a characteristic pattern of 
trabecular bone emerging from the cortex of the ossicles 
(Fig. 3B). Likewise, microcomputed tomographic (pCT) 
analysis revealed a marked increase in percent bone 
volume of the ossicles in mice treated with PTH (48.2 i 
I .9'% (PTH) versus 30 * 3.1% (vehicle), p < 0.01, Fig. 
3D and E). Although the number of osteocytes in the 
tissue-engineered cortical bone tended to increase with 
anabolic administration of PTH, it did not reach sta- 
tistical significance. No significant differences between 
groups were observed in cortical bone width and in the 
overall dimensions of the ossicles (data not shown). 
Discussion 
The results of the present study demonstrate that 
ectopic tissue-engineered ossicles derived from trans- 
planted BMSCs are responsive to catabolic and ana- 
bolic treatments with systemic PTH and thus may serve 
as an in vivo model to study skeletal homeostasis. One 
of the most significant findings of this study was the 
substantial increase in trabecular bone following 
treatment with anabolic doses of PTH as demonstrated 
by histomorphonietric and pCT analyses. Currently, 
increasing interest exists for the use of anabolic agents 
in the treatment of metabolic bone diseases, particu- 
larly osteoporosis. In fact, among several potential 
anabolic agents, PTH is considered the most promising 
agent for the treatment of osteoporosis in women and 
men [7,21]. 
Our results also demonstrate that anabolic treatment 
with PTH positively affects growing skeletal structures 
like the ectopic ossicles. The basic mechanisms by which 
exogenous PTH exerts anabolic actions in bone are still 
poorly understood; however, these effects have been 
associated with increases in osteogenic cell proliferation 
and differentiation [22] and prolonged osteoblast sur- 
vival [ 141. Nishida et al. demonstrated that cultured 
BMSCs isolated from rodent long bones following a 
3-week regimen with anabolic doses of PTH( 1-34) gen- 
erated more alkaline phosphatase positive-colony 
forming unit-fibroblastic colonies (CFU-F), suggesting 
that these cells were already committed to the osteo- 
blastic lineage. These data correlated with significant 
increases in parameters related to bone formation in- 
cluding bone mineral density [22]. Therefore, PTH may 
be stimulating anabolic actions in bone in part by pos- 
itively regulating the pool of osteoprogenitor cells 
available to differentiate into bone-forming cells. Inter- 
estingly, recent studies on the effects of PTH in devel- 
oping bone suggests that PTH is also critical to achieve 
normal fetal endochondral bone formation by affecting 
cartilage mineralization and osteoblast proliferation, 
differentiation and survival in the endosteum and pri- 
mary spongiosa [6,20]. 
The substantial increase in trabecular bone in the 
ossicles indicates that ectopic tissue-engineered bone 
may also provide a powerful, new strategy to test skel- 
etal pharmacotherapeutic agents designed to improve 
bone quality. Skeletal homeostasis in response to bio- 
logic factors is usually studied in model systems that 
include normal, gonadectomized, transgenic animals, 
and more recently, transplanted bone fragments 
[1,3,10,18]. Despite their valuable role, they have limited 
application to bone tissue engineering because they 
evaluate remodeling responses in fully developed native 
bone. The ectopic tissue-engineered bone model system 
offers the advantage that several and distinct ossicles can 
be generated in a single host and individual ossicles can 
be retrieved at different time points without sacrificing 
the animal. 
This model system goes beyond the application of cell 
transplantation systems for skeletal regeneration pur- 
poses. By demonstrating that the newly formed bone 
behaves as normal skeletal tissue, cell-based bone tissue- 
engineering strategies may be utilized in conjunction 
with anabolic agents, such as PTH, to amplify and 
further optimize de novo bone formation in regenerating 
skeletal sites. In fact, adding a physiologic stimulus to 
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Fig. 3. PTH induced an anabolic response in ectopic tissue-engineered bone. (A) Microradiographic image of three ossicles exposed to vehicle (left) or 
PTH treatment (right). (B) H & E stained histological sections of newly formed bone derived from BMSC transplantation. Note the increase in 
trabecular bone (T) and marrow cellularity (M) in the ossicle exposed to anabolic doses of PTH (right). (C) Quantification of trabecular bone area 
per total area of ossicle by histomorphometric analysis in representative implants from PTH- (n = 7) and vehicle control-treated animals (n = 4), 
* p  < 0.05. (D) pCT images of representative ossicles derived from animals treated with vehicle control (left) or PTH (right). (E) Quantification of the 
total bone volume relative to the total volume of the implant by pCT analysis in representative ossicles derived from PTH- ( n  = 3)  and vehicle 
control-treated animals (n  = 3), * p  < 0.01. 
enhance the regenerative capacity of engineered bone in health and disease and design studies to: (a) eluci- 
may result in bone that more effectively mimics the date cellular/molecular mechanisms in bone regenera- 
native tissue. tion and homeostasis (i.e., signaling pathways); (b) 
Moreover, this versatile system may assist a wide study normal or aberrant cell-to-cell interactions in 
range of scientists from academia to the pharmaceutical the bone marrow microenvironment (i.e., tumor cell/ 
industry to better understand in vivo bone physiology bone cell interactions); and (c) evaluate the efficacy of 
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pharmacotherapeutic agents that modulate 
over in vivo. 
bone turn- 
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